Patients requiring daily systemic corticosteroids are not eligible; patients must not have received systemic corticosteroids within days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= days must have elapsed since last dose of corticosteroid; Note: use of topical or inhaled corticosteroids will not render a patient ineligible Has received more than days of systemic corticosteroids for aGVHD. Any condition that would prohibit administration of corticosteroids Conditions that would prohibit administration of corticosteroids Patients must not have received any immunosuppressive medication within days prior to sub-study registration and must not be planning to receive these medications while on protocol therapy; systemic corticosteroids must be stopped at least hours prior to sub-study registration; however, intranasal and inhaled corticosteroids are allowed at any time before and during protocol therapy It is preferred, but not required, that corticosteroids and hydroxyurea should start only after all diagnostic samples have been obtained; however, if the patient was previously on corticosteroids and/or hydroxyurea, this is allowable provided that the patient still has measurable disease at time of the bone marrow aspirate\r\n* Corticosteroids and/or hydroxyurea, as well as any of the other therapies mentioned (with the exception of IV cyclophosphamide), may continue to be administered, at physician discretion, until day prior to blinatumomab administration\r\n** IV cyclophosphamide must be discontinued at least days prior to blinatumomab administration Has received systemic immunosuppressive treatments, aside from systemic corticosteroids within three months of start of study drug Patients receiving systemic corticosteroids (patients off steroids for at least hours are eligible) Has received systemic immunosuppressive treatments, aside from systemic corticosteroids, within three months of start of study drug Are receiving increasing doses of corticosteroids Patients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for >= months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > month or who have been off of corticosteroids for at least weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off of enzyme-inducing anticonvulsants for > weeks Use of corticosteroids (glucocorticoids) within days of the MILs collection TREATMENT: Patients receiving systemic corticosteroids Received corticosteroids within the past week Patients receiving systemic corticosteroids (patients off steroids for at least hours are eligible) Patients receiving corticosteroids are eligible for this trial Participants who have received or more systemic treatment for cGvHD in addition to corticosteroids CNI for cGvHD Patients that transition from active aGvHD to cGvHD without tapering off corticosteroids CNI and any systemic treatment * Patients receiving up to mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed. No history of long-term use of corticosteroids or concurrent short term use of corticosteroids is allowed Subjects, who have received previous systemic corticosteroids treatment or poorly absorbable corticosteroids for the treatment of aGVHD, for longer than days ( hours). Subject who used corticosteroids (excluding inhalers, eye-drops, and dermatologic corticosteroids) within weeks prior to surgery; Patient is receiving unstable or increasing doses of corticosteroids. Systemic corticosteroids are permissible in the following circumstances:\r\n* Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (=< days) must have been discontinued at least days prior to study treatment\r\n* Ongoing administration of a stable dose of corticosteroid therapy (previously received for >= days) is permissible provided there is evidence of measurable disease and there will be no increase in steroid dose during the clinical trial Patients receiving systemic corticosteroids (patients off steroids for at least hours are eligible) No systemic corticosteroids (unless physiologic replacement dosing) within days of enrollment Patients who have received high doses of systemic corticosteroids for the treatment of their ATL within weeks prior to the start of therapy Concurrent systemic treatment or prior therapy within weeks for SMM; NOTE: Treatment with corticosteroids for other indications is permitted Ongoing immunosuppressive treatment at the time of the start of voruciclib therapy, including systemic or enteric corticosteroids except as follows: During study therapy, subjects may use systemic, topical, or enteric corticosteroids, if needed Patients receiving systemic corticosteroids greater than -weeks in duration within months of study entry must have evidence of adequate adrenal function based upon morning plasma cortisol concentration or ACTH (cosyntropin) stimulation test Presence of immunosuppressive conditions, including administration of any medications or treatments that may adversely affect the immune system such as allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids (oral or injectable) during months prior to enrollment; inhaled and topical corticosteroids allowed Current use of immunosuppressive agents or systemic corticosteroids; topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed; patients who have received systemic\r\ncorticosteroids =< days prior to starting study drug will be excluded Need for systemic treatment with corticosteroids for cGVHD Received any previous systemic treatment for cGVHD with the exception of corticosteroids administered for cGVHD within the hours prior to signing the informed consent form. Corticosteroids Concurrent systemic corticosteroids, cytokines, and immunomodulatory therapy (e.g. interferons) Patients receiving concurrent corticosteroids at the time protocol therapy is initiated other than for physiologic maintenance treatment No systemic corticosteroids (unless physiologic replacement dosing) within days of enrollment No systemic corticosteroids (unless physiologic replacement dosing) within days of enrollment Patients who are receiving systemic corticosteroids Use of systemic corticosteroids Chronically treated with systemic doses of immunosuppressive drugs such as cyclosporin, ACTH, or corticosteroids. Any condition that requires the use of corticosteroids outside of corticosteroids defined in the protocol after day of therapy Patients who are on corticosteroids or immunosuppressants are not eligible; a week wash-out period for is required before registration Has received systemic immunosuppressive treatments, aside from systemic corticosteroids (such as methotrexate, chloroquine, azathioprine, etc) within six months of registration % prednisolone acetate ophthalmic suspension and any other corticosteroids. Current use of systemic corticosteroids or use of systemic corticosteroids within weeks of enrollment (inhaled corticosteroids for asthma or chronic obstructive pulmonary disease [COPD] are permitted as are other non-systemic steroids such as topical corticosteroids) Patients receiving active immunosuppressive agents or chronic use of systemic corticosteroids within days of vaccine treatment\r\n* Note: special considerations for vaccination: study-related treatments may be given after short-term steroid use (=< days) with prior approval by the protocol chair and investigational new drug (IND) sponsor Immunosuppressive therapy including systemic corticosteroids except for maintenance dosing for adrenal insufficiency Current use of immunosuppressive drugs or use of corticosteroids, except for inhaler, topical corticosteroids, or dexamethasone in the premedication for docetaxel. Subject requires or is likely to require more than a two-week course of corticosteroids for intercurrent illness; subject must complete the course of corticosteroids weeks before screening to meet eligibility Patients being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids Conditions that would prohibit administration of corticosteroids No systemic corticosteroids (unless physiologic replacement dosing) within days of enrollment Any condition that requires or is likely to require treatment with systemic corticosteroids within the core study period and short term follow-up Subjects who require or are likely to require more than a two-week course of corticosteroids for intercurrent illness; subjects must complete therapy prior to enrollment; topical corticosteroids should be stopped at least weeks prior to enrollment and systemic corticosteroids should be stopped at least weeks prior to enrollment Conditions that would prohibit intermittent administration of corticosteroids for T-DM premedication. Patients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for >= weeks (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > month or who have been off of corticosteroids for at least weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off of enzyme-inducing anticonvulsants for > weeks Treatment with corticosteroids within weeks prior to enrollment Patients taking systemic corticosteroids The use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least days without recurrence of symptoms prior to starting trial therapy; corticosteroids for other indications is allowed Current use of systemic corticosteroids More than weeks since prior systemic corticosteroids Corticosteroids by aerosol are allowed Patients who have received systemic chemotherapy (corticosteroids not included) less than weeks prior to the start of this protocol Any therapy =< weeks prior to registration; NOTE: Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion Patients receiving unstable or increasing doses of corticosteroids Patient received corticosteroids within weeks prior to the first dose. At least weeks beyond corticosteroids. Patients who have received corticosteroids =< weeks prior to starting study drug; the exception is patients receiving low dose steroids for CNS disease; otherwise, systemic corticosteroids should not be administered with BKM ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Daily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous days Any use of systemic corticosteroids within days of treatment initiation. Patients requiring systemic corticosteroids (unless patients have had no corticosteroids within weeks prior to start of study) Subjects require or are likely to require more than a -week course of corticosteroids for intercurrent illness. Subjects must have completed the course of corticosteroids at the time of apheresis to meet eligibility. No prior therapy is allowed except for the following:\r\n* Short courses of corticosteroid (defined as =< days of corticosteroids within the -weeks preceding registration) are allowed\r\n** Participants who have been on corticosteroids chronically (defined as more than days of corticosteroids within the -weeks preceding registration or more than days of corticosteroids over the preceding months) are not eligible; previous courses of inhaled corticosteroids of any duration are allowed\r\n* A single dose of intrathecal cytarabine (at the time of the diagnostic lumbar puncture) is allowed prior to registration; if patient has received intrathecal (IT) cytarabine prior to informed consent for protocol treatment, day IT cytarabine should not be administered\r\n* Emergent radiation to the mediastinum or other life-threatening masses is allowed prior to registration The subject requires or is likely to require more than a -week course of corticosteroids of > mg Treatment with systemic corticosteroids within weeks prior to the start of the treatment; patients that require inhaled or low-dose corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, mineralocorticoids are allowed Patients who are currently receiving or plan to receive corticosteroids except as described below \r\n* Systemic corticosteroids may be administered for cytoreduction up to hours prior to the start of protocol therapy, as a premedication for InO and as treatment for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone for documented adrenal insufficiency; corticosteroids are not allowed for other indications No oral corticosteroids days before initiating combinations TEW-/POM; inhaled corticosteroids are permitted Has had systemic corticosteroids within weeks of the first dose of protocol-related radiation or MK- No prior therapy is allowed except for the following:\r\n* Corticosteroids: short courses of corticosteroid (defined as =< days of corticosteroids within the weeks preceding registration) are allowed prior to registration; note: if patient has received pre-treatment with corticosteroids, they should not receive steroid prophase\r\n** Participants who have been on corticosteroids chronically (defined as more than days of corticosteroids within the weeks preceding registration or more than days of corticosteroids over the preceding months) are not eligible\r\n* IT cytarabine: a single dose of intrathecal cytarabine (at the time of the diagnostic lumbar puncture) is allowed prior to registration; if patient has received IT cytarabine prior to registration, day IT cytarabine should not be administered\r\n* Emergent radiation therapy: emergent radiation to the mediastinum or other life-threatening masses is allowed prior to registration Participants who have received more than days of corticosteroids in the preceding weeks or more than days of corticosteroids in the preceding months are not eligible Corticosteroids should not be used during chemotherapy administration as an antiemetic Any condition that would prohibit administration of corticosteroids Patient must have received no prior radiation therapy or chemotherapy other than corticosteroids; corticosteroids are allowable for all patients Any use of systemic corticosteroids in the prior weeks Patients requiring treatment with corticosteroids are eligible Patients receiving chronically dosed corticosteroids within days prior to enrollment are not eligible for this trial Conditions that would prohibit administration of corticosteroids Immunosuppressive medications including systemic corticosteroids unless used for adrenal replacement, appetite stimulation, acute therapy for asthma or bronchitis exacerbation (=< weeks), or antiemesis Current treatment or treatment within weeks of screening with drugs known to reduce\n serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet,\n macrolide antibiotics (such as erythromycin, azithromycin), large doses of\n corticosteroids (> mg/day of prednisone or equivalent), or any IV use of\n corticosteroids. In addition, long-term use (defined as ongoing use for ? weeks) of\n corticosteroids within weeks of screening is prohibited Use of systemic corticosteroids or other immunosuppressive agents within the previous weeks of study enrollment Patients taking systemic corticosteroids Subjects who cannot tolerate a corticosteroid taper, that is, begin corticosteroids at . mg/kg per day, demonstrate response, but progress before a % decrease from the initial starting dose of corticosteroids is achieved. Patients NOT receiving systemic immune suppressive therapy for treatment of active GVHD (topical skin and GI corticosteroids are allowed). Concurrent, recent (? weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or Requiring corticosteroids or anticonvulsants in the prior days Subject is currently receiving or requires treatment with immunosuppressive agents or immunosuppressive doses of systemic corticosteroids (unless used to treat drug-related adverse events).Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption), and some uses of systemic corticosteroids are permitted as per Section .. Concurrent, recent (? weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or Requiring corticosteroids or anticonvulsants in the prior days Have had any chemotherapy or systemic corticosteroids within weeks of study entry. Concurrent, recent (? weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or Daily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous days. Neurologically stable defined as receiving no, stable, or tapering doses of corticosteroids for >= days prior to drug dosing; treatment with corticosteroids during the study is allowed, and can be adjusted by the investigator during the study; changes in steroid dose are incorporated into the Revised Assessment in Neuro-Oncology (RANO) imaging criteria Systemic (oral or parenteral) corticosteroids within days of study entry Current use of systemic corticosteroids Patients receiving corticosteroids are not eligible; patients must have been off corticosteroids for days prior to start of chemotherapy Subjects on systemic intravenous or oral corticosteroid therapy with the exception of physiologic doses of corticosteroids (=< the equivalent of prednisone mg/day) or other immunosuppressives such as azathioprine or cyclosporin A are; for these subjects these excluded treatments must be discontinued at least weeks prior to enrollment for recent short course use (=< days) or discontinued at least weeks prior to enrollment for long term use (> days); in addition, the use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on study Concurrent or planned concurrent treatment with systemic high dose (immunosuppressive) corticosteroids or treatment with systemic corticosteroids within weeks of baseline Patients who have received oral or parenteral corticosteroids within weeks of study entry or who have a clinical requirement for ongoing systemic immunosuppressive therapy not related to chemotherapy administration. Patients on immunosuppressants, systemic corticosteroids, or any other investigational product. Is dependent on, currently or has received within the past weeks corticosteroids (hormone replacement therapy, topical corticosteroids and occasional inhaled corticosteroids are allowed). Has received systemic immunosuppressive treatments, aside from systemic corticosteroids as described below (such as methotrexate, chloroquine, azathioprine, etc) within six months of start of study drug Current or recent (=< weeks) use of immunosuppressive medications including systemic (inhaled, oral, or intravenous [IV]) corticosteroids; Note: use of corticosteroids in doses not exceeding those used for adrenal replacement is acceptable Systemic corticosteroids use =< weeks, regardless of indication; note: patients who are on inhaled corticosteroids are eligible Patients receiving concurrent corticosteroids for reason(s) other than for physiologic maintenance treatment; patients should otherwise discontinue corticosteroids prior to registration to study Concurrent maintenance corticosteroids; No previous use of corticosteroids for autoimmune complications that have developed since the initial diagnosis of CLL; prior use of corticosteroids for reasons other than treatment of autoimmune complications is allowed History of long-term use of corticosteroids or concurrent short-term use of corticosteroids is not allowed; short-term corticosteroid use must be discontinued at least weeks prior to study treatment Brain metastases that are symptomatic or untreated or not stable for >= months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > month or who have been off corticosteroids for at least weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off enzyme-inducing anticonvulsants for > weeks Subjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the FOLFIRINOX or gemcitabine/nab-paclitaxel regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study. Treatment with corticosteroids within weeks Clinically stable and off corticosteroids for at least weeks prior to study enrollment Within weeks of treatment initiation (day ), have received treatment with:\r\n* Local radiation therapy\r\n* UVB therapy\r\n* PUVA\r\n* Any topical chemotherapy\r\n* Photopheresis\r\n* Systemic retinoids, corticosteroids, immune response modifiers (other than imiquimod), interferon inducers, chemotherapeutic agents, biologic agents including interferon\r\n* Topical corticosteroids or retinoids Past or current anti-cancer treatment except corticosteroids of less than days duration in total Currently being treated with bronchodilators or corticosteroids Past or current anti-cancer treatment except corticosteroids during less than one week. Long-term use of systemic corticosteroids Patients receiving oral corticosteroids within days of enrollment. Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ? days prior to initiation of study treatment Patients who have been treated for at least two weeks with stable doses of corticosteroids to address conditions unrelated to their malignancy will be allowed to continue this treatment during enrollment on the current trial Require concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy) Subject requires or is likely to require more than a two week course of corticosteroids for intercurrent illness; subject must complete the course of corticosteroids weeks before screening to meet eligibility Supraphysiologic doses of corticosteroids within weeks Cytotoxic chemotherapy =< weeks, or biologic or novel targeted therapies =< weeks, or corticosteroids =< weeks, prior to registration; patients may be receiving chronic corticosteroids if they are being given for disorders other than myeloma Patients who have received systemic chemotherapy (corticosteroids not included) less than weeks prior to the start of this protocol Subjects with a medical condition requiring chronic systemic corticosteroids Any other disease requiring long-term corticosteroids or immunosuppressants Subjects must be receiving systemic corticosteroids. Participants must be receiving systemic corticosteroids. Treatment with methylprednisolone/systemic steroids must have been initiated within hours prior to the first dose of study treatment after enrollment Subjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the mFOLFIRINOX regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study. No ongoing requirement for corticosteroids Daily requirement for corticosteroids (except for inhalation corticosteroids). Use of topical corticosteroids at or near the intended administration site; Patient has discontinued all corticosteroids for that indication for at least weeks; Patients currently receiving systemic corticosteroids Patients on systemic corticosteroids (except for patients on stable doses of hormone replacement therapy such as hydrocortisone), or other immunosuppressants (e.g., infliximab, mycophenolate mofetil) are excluded No systemic or inhaled corticosteroids within days prior to initiation of protocol therapy; NOTE: use of topical corticosteroids and/or eye drops containing glucocorticosteroids is acceptable For patients on corticosteroids, they must have been on a fixed dose for week prior to entry if clinically recommended Patients on corticosteroids for any reason Patients who have received systemic corticosteroids =< weeks prior to starting study drug; systemic corticosteroids should not be administered with BKM (usage of steroids as premedications and anti-emetics for paclitaxel and carboplatin, per MSKCC guidelines, is allowed; steroids given as part of pre-medications for imaging studies are not exclusionary) Patients taking systemic corticosteroids Corticosteroids discontinued ? days of initiating therapy patients receiving hydroxyurea or corticosteroids that has not been discontinued at least week after initiation of nilotinib Prior corticosteroids allowed Patients must not require use of systemic corticosteroid within days prior to registration or during protocol treatment; patients with preexisting severe autoimmune disease requiring systemic corticosteroids or ongoing immunosuppression are not eligible Patients must not be receiving any of the following concomitant medications:\r\n* Pharmacologic doses of systemic corticosteroids unless for CNS metastatic or primary disease; for patients with CNS metastatic or primary tumors receiving corticosteroids, they should be on a stable or decreasing dose over the days prior to registration; for all patients, receipt of systemic physiologic replacement steroids, topical, and/or inhaled corticosteroids is acceptable\r\n* Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic heparins Treatment with high dose systemic corticosteroids or continuous use of other immunosuppressants within the past days Current use of corticosteroids defined as oral, intravenous (IV), or injections of corticosteroids in the past weeks\r\n* If the patient is only prescribed a short-term, time-limited dose of oral, intravenous (IV), or injections of corticosteroids, then they may be rescreened for eligibility once they are >= weeks post-completion of their course of corticosteroids Use of oral corticosteroids or topical corticosteroids in the irradiation area Short course systemic corticosteroids is permissible for disease control, improvement of performance status or non-cancer indication if =< days and must be discontinued prior to study treatment Patients must not have received oral corticosteroids, intramuscular corticosteroids, or intra-articular steroids for joint symptoms within days prior to registration Treatment with high dose systemic corticosteroids or continuous use of other immunosuppressants within the past months Autoimmune disorders, transplant recipients, other immunosuppression including any concurrent condition requiring the use of immunosuppressive/ immunomodulating agents; Exception: eye drop-containing and infrequent inhaled corticosteroids are permissible; topical corticosteroids are permissible at locations other than the administration site (upper arm); Note: All systemic corticosteroids must be discontinued at least weeks prior to randomization; inhaled corticosteroids must be discontinued >= hours prior to randomization and courses of more than weeks are not permissible within weeks of randomization Patients on systemic corticosteroids (oral or intravenous) Skin conditions that require consistent use of topical corticosteroids or other local or systemic therapy that may interfere with interpretation or description of skin-related adverse events linked to vaccination Any use of oral corticosteroids =< weeks prior to registration/randomization Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids for greater than days, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin (IVIG) within days prior to study entry Immunosuppressive therapy including systemic corticosteroids except for maintenance dosing for adrenal insufficiency Treatment within months with immunomodulatory therapy (e.g., interferons, immunoglobulin therapy, interleukin receptor antagonist or systemic corticosteroids); short-term systemic corticosteroids or topical or intra-articular steroids are acceptable, at the discretion of the Investigator Current or prior systemic use of corticosteroids in the past month Corticosteroids: no restrictions currently or previously required systemic immunosuppressive or immunomodulatory therapy (including corticosteroids administered by systemic route) and/or